Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has been awarded an A$1.4 million tax refund under the Australian Government’s Research and Development (R&D) Tax Incentive Scheme.
The refund covers eligible R&D activities for the year ending December 31, 2023.
Incentivising research
The R&D Tax Incentive Scheme encourages Australian companies to engage in research by offering a refundable tax offset on their initiatives, helping businesses recover some of their R&D-related expenses.
Anteris plans to use the refund to continue the development of its key technologies, including the ADAPT® tissue, DurAVR® transcatheter heart valve (THV) and the ComASUR® Delivery System.
Read: Anteris Technologies' transcatheter heart valve continues to demonstrate its potential
These technologies are essential to the company’s upcoming FDA pivotal trial for the DurAVR® THV, aimed at treating severe aortic stenosis.
Leader in structural heart market
Anteris is a leader in the structural heart market, focused on providing innovative solutions to treat heart disease.
Its DurAVR® THV, developed in collaboration with top cardiologists and cardiac surgeons, is the first transcatheter aortic valve to use a single piece of bioengineered tissue, closely mimicking the function of a healthy human valve.
With the continuing support of the R&D tax refund, Anteris is advancing towards delivering superior clinical outcomes for patients with unmet needs in the structural heart market.
Watch: Anteris Technologies and v2vmedtech achieve concept lock for new TEER system